Eduovisual
Biostatistics & Population Health
Shared decision-making: data presentation and risk communication
— Preference-sensitive decisions: multiple reasonable options with different risk/benefit profiles (e.g., PSA screening, lung cancer screening with LDCT, anticoagulation for AF with CHA₂DS₂-VASc 1, prostate cancer treatment, breast reconstruction).
— Close trade-offs: benefits and harms are similar in magnitude (e.g., statin for primary prevention with 10-yr ASCVD 7.5–10%).
— Value-laden outcomes: quality vs quantity of life (advance care planning, dialysis initiation in elderly, chemotherapy at end of life).
— CMS-mandated SDM: lung cancer screening (LDCT), left atrial appendage closure (Watchman), ICD primary prevention, carotid stenting — documentation is a reimbursement requirement.
— True emergencies with a clear standard of care (STEMI, anaphylaxis).
— Decisions where one option is overwhelmingly superior (antibiotics for bacterial meningitis).
— Public health mandates where individual choice is constrained (reportable diseases, court-ordered treatment).
Board pearl: On Step 3, when a stem describes a "close call" preventive or screening decision and asks for the next best step, the answer is usually "discuss risks and benefits with the patient" — not "order the test" and not "decline the test." SDM is the default when evidence supports multiple reasonable paths.
— A patient at a threshold age or risk for screening (55-yr-old smoker considering LDCT; 70-yr-old asking about PSA; 45-yr-old considering mammography start).
— A patient with borderline indication for a chronic therapy (statin with 10-yr ASCVD 8%; anticoagulation with CHA₂DS₂-VASc 1; bisphosphonate for osteopenia with FRAX near threshold).
— A patient declining or hesitant about a recommended intervention (vaccine hesitancy, refusing colonoscopy, considering stopping dialysis).
— A family meeting around goals of care, code status, or transitions (hospice referral, feeding tube in dementia).
— Patient's baseline understanding ("What have you heard about…?") — corrects misconceptions before they harden.
— Values and goals ("What matters most to you about your health right now?") — distinguishes longevity-focused from function-focused patients.
— Prior experiences (family member with cancer, bad outcome from a procedure) that anchor risk perception.
— Health literacy and numeracy — assessed indirectly via teach-back; do not rely on years of education.
— Cultural, religious, and family decision-making norms — some patients defer to family or clergy; ask explicitly.
— Financial/insurance context — cost is a legitimate factor; out-of-pocket burden should be raised, not hidden.
Key distinction: Informed consent documents that risks/benefits/alternatives were disclosed for a specific intervention; shared decision-making is the upstream process of co-deliberation. A signed consent form does not prove SDM occurred — the chart note describing the conversation does. On exam stems, look for whether the question is testing consent legality (document, witness, capacity) vs SDM quality (values elicited, options compared, preference honored).
— Ask: what the patient already knows or wants to know.
— Tell: information in small, jargon-free chunks (max ~3 facts before pausing).
— Ask: for teach-back ("To make sure I explained this well, can you tell me in your own words…?").
— "high blood pressure" not "hypertension"; "kidney" not "renal"; "spread" not "metastatic"; "chance" not "probability."
— Avoid "positive/negative" results — patients often invert the valence; say "shows cancer" vs "does not show cancer."
— Pause after delivering numbers; silence allows processing.
— Limit each visit to one major decision when feasible.
— Offer a decision aid (video, pamphlet, web tool) for the patient to review between visits when the decision is non-urgent.
Step 3 management: When a stem asks how to confirm a patient understood discharge instructions or a new diagnosis, the answer is almost always "ask the patient to explain the plan back in their own words" (teach-back) — not "give a written handout" alone, not "ask if they have questions" (yes/no questions miss comprehension gaps). Written materials supplement but do not replace verbal teach-back, especially at care transitions where readmission risk is highest.
— Studies consistently show patients (and clinicians) overestimate benefit when given relative numbers and underestimate when given absolute. SDM standard: present absolute risks for both arms, plus the difference.
— Use consistent denominators ("3 in 100" vs "30 in 1,000" — pick one and stick with it).
— Prefer natural frequencies ("7 out of 100 women") over percentages or 1-in-X ratios ("1 in 14" — patients struggle to compare 1-in-X numbers).
— Provide both benefits and harms in the same format and timeframe.
— Anchor to a familiar time horizon (10-year, lifetime, or per-decade).
— Show baseline risk so the patient sees the floor before the intervention modifies it.
— Mixing RRR for benefits with AR for harms (asymmetric framing that biases toward treatment).
— Verbal descriptors alone ("rare," "common") — interpretation varies 10-fold across patients.
Board pearl: When a stem gives you a drug that "reduces stroke by 50%" but the baseline annual stroke risk is 1%, the ARR is 0.5%/year and NNT is 200/year. The exam often pairs an impressive RRR with a trivial ARR to test whether you can translate. The SDM-correct disclosure is the absolute numbers.
— Reduce denominator neglect and framing bias.
— Allow side-by-side comparison of treatment vs no-treatment arms.
— Present options, outcomes, and probabilities in balanced fashion.
— Include values-clarification exercises.
— Are updated with current evidence and disclose conflicts.
— MyHealthFinder / USPSTF patient-facing summaries.
— ASCVD Risk Estimator Plus (ACC/AHA) — provides 10-yr and lifetime risk with bar chart.
— CHA₂DS₂-VASc + HAS-BLED displayed side-by-side for AF.
— Lung Decision Precision and shouldiscreen.com for LDCT.
— Option Grid one-page comparison tables.
Step 3 management: For a patient considering lung cancer screening with LDCT (eligible: 50–80, ≥20 pack-years, current smoker or quit <15 yrs), the CMS-required SDM visit must use a decision aid and document the discussion — not just the order. Missing this documentation is a billing and quality-measure failure even if the scan is clinically indicated.
— Low complexity, high evidence, low preference sensitivity: standard recommendation suffices (vaccinate the 65-yr-old against pneumococcus; treat the strep throat).
— Moderate complexity: brief SDM — present recommendation + main alternative + invite questions (statin in 10-yr ASCVD 15%).
— High complexity, preference-sensitive: full SDM with decision aid, possibly a return visit (prostate cancer treatment, dialysis initiation, ICD).
— Patient cannot state the options in their own words.
— Patient parrots clinician language without context ("you said I should…").
— Decision is driven by a single family member overriding the patient.
— Patient agrees in clinic but no-shows the procedure → unresolved conflict.
— Visit 1: introduce decision, provide decision aid, no decision made.
— Visit 2 (1–2 weeks later): revisit with values clarified, finalize plan.
— Honor the preference for clinician-led decision-making but still disclose key risks/benefits and document the patient's stated delegation. This is itself an autonomous choice.
Key distinction: Decisional conflict (uncertainty about which path to take) is normal and resolvable with more information or time; decisional regret (retrospective dissatisfaction with the choice) correlates more with the quality of the decision process than the outcome itself. Patients who feel heard regret less, even when outcomes are poor — a core SDM justification.
— Present: 10-yr risk of MI/stroke with and without statin (e.g., 12% → 9%, ARR 3%, NNT 33 over 10 yrs).
— Disclose: myalgia ~5–10%, new-onset diabetes ~0.2%/yr, no clinically meaningful cognitive effect.
— Discuss lifestyle as adjunct, not alternative, when risk is intermediate-high.
— Present annual stroke risk by CHA₂DS₂-VASc vs annual major bleed risk by HAS-BLED.
— DOACs preferred over warfarin in non-valvular AF (less ICH, no INR monitoring); discuss reversal agents, cost, renal dosing.
Board pearl: When asked the most appropriate next step for a patient with intermediate ASCVD risk and a "borderline" decision, choose "discuss risks and benefits of statin therapy and shared decision-making" over "start moderate-intensity statin" or "recommend lifestyle only." High-risk (≥20%) patients get a statin recommendation; intermediate get SDM.
— Diagnosis and nature of the proposed procedure.
— Risks (material risks a reasonable patient would want to know — "reasonable patient" standard in most US jurisdictions; some retain "reasonable physician" standard).
— Benefits and likelihood of success.
— Alternatives (including doing nothing).
— Capacity to consent and voluntariness (no coercion).
— Left atrial appendage occlusion (Watchman): CMS requires documented SDM visit using a decision aid, with an independent non-interventional clinician.
— ICD primary prevention: CMS-mandated SDM using an approved decision aid for non-ischemic and ischemic cardiomyopathy.
— Knee/hip replacement, spinal fusion, hysterectomy for benign disease, bariatric surgery, prostatectomy vs radiation vs surveillance — all preference-sensitive.
— Cardiac catheterization for stable CAD (post-ISCHEMIA): medical therapy is often non-inferior; SDM essential.
CCS pearl: On a CCS case requiring a procedure, order "obtain informed consent" as a discrete action before the procedure itself. For CMS-flagged procedures (Watchman, ICD, LDCT), also document a shared decision-making visit — missing this step is both a quality and a billing failure even when the procedure goes well.
— Understanding (can repeat back relevant information).
— Appreciation (applies it to own situation, not abstract).
— Reasoning (compares options logically).
— Expression of a consistent choice.
— Tools: MacArthur Competence Assessment Tool (MacCAT-T); bedside structured questions.
— Court-appointed guardian → durable power of attorney for healthcare → spouse → adult child(ren) → parent → sibling → close friend.
— Standards: substituted judgment (what would the patient want?) preferred over best interest (what would a reasonable person want?).
— Frame around function and independence, not just survival.
— Use time-to-benefit framing for screening (e.g., colonoscopy benefit takes ~10 yrs; consider deprescreening when life expectancy <10 yrs).
— Discuss deprescribing: stopping statins, BP meds, bisphosphonates near end of life is appropriate SDM.
— Hearing/vision deficits — ensure aids in place, written materials in large print, quiet room.
Step 3 management: When an 82-year-old with multiple comorbidities asks about continuing screening colonoscopy or mammography, the right answer is shared discussion incorporating life expectancy and patient values, often stopping screening if life expectancy <10 years. Do not auto-order screening based on age alone; do not auto-stop without conversation. ePrognosis is a useful prognostic adjunct.
— Children <7 typically lack assent capacity; parental permission sufficient.
— Ages 7–13: developmentally appropriate assent sought; dissent should be considered though not always determinative.
— Adolescents ≥14: increasing weight given to their preferences; mature-minor doctrine in many states allows independent consent for specific issues (contraception, STI testing, mental health, substance use treatment) without parental notification.
— Emancipated minors (married, military, parents themselves, court-emancipated): full consent rights.
— Vaccine refusal in children: AAP recommends persistent education; do not dismiss families immediately; document discussion; CPS only if clear medical neglect with serious imminent harm.
— Pregnant patient retains full autonomy, including the right to refuse interventions even when fetal outcome is threatened (court-ordered cesarean is ethically and legally disfavored).
— Discuss maternal-fetal trade-offs transparently (e.g., antiepileptic choice, anticoagulation for mechanical valve, chemotherapy in pregnancy).
— Genetic screening (cell-free DNA, CVS, amnio): preference-sensitive — present sensitivity/specificity, PPV at her age, and what she would do with results.
— Use professional medical interpreters (in-person, phone, video) — not family members and never minor children (HHS/CMS standard).
— Address the patient directly, even via interpreter.
— Some cultures emphasize family-based decision-making; ask the patient how they want information shared and who they want involved.
— Religious considerations: Jehovah's Witnesses (blood products), Christian Scientists (some refuse medical care) — document specific refusals.
Board pearl: A 16-year-old presents for STI testing or contraception without parental knowledge — in virtually all states, provide confidential care; parental notification is not required and may be prohibited. The Step 3 trap answer "notify parents" is wrong; the correct answer is to provide services and counsel about confidentiality limits.
— Lack of SDM correlates with higher rates of low-value PSA screening, elective PCI for stable CAD, end-of-life ICU care that patients didn't want.
— Overdiagnosis (detecting disease that would never have caused harm) is rarely discussed without a decision aid — patients overestimate screening benefit by 5–10 fold without it.
— Most malpractice suits cite communication failures, not technical errors, as the trigger.
— Documented SDM with values elicitation is protective evidence.
— Failure-of-informed-consent claims survive when the alleged undisclosed risk is material and the patient would have declined had they known.
— Poor numeracy, limited English proficiency, low health literacy, and minoritized racial/ethnic groups receive less SDM on average — widening outcome gaps.
— Structural solution: standardized decision aids, certified interpreters, plain-language defaults.
Key distinction: Adverse outcome alone is not malpractice; adverse outcome + breach of standard of care + causation + damages is. A well-documented SDM conversation showing the patient understood and accepted a known risk is one of the strongest defenses against a "failure-to-warn" claim — even when the bad outcome materializes.
— Disagreement between patient/family and team that persists after good-faith communication.
— Questions about decisional capacity that aren't resolvable by the primary team.
— Surrogate appears to act against patient's prior wishes or best interest.
— Requests for non-beneficial or potentially inappropriate treatment.
— Resource allocation conflicts (transplant listing, ICU bed during crisis standards).
— Conscientious objection by a clinician.
— Document capacity assessment, the recommendation, the discussion, alternatives offered, and the refusal.
— Continue therapeutic relationship; do not abandon.
— AMA discharge (against medical advice): still provide discharge instructions, prescriptions for needed meds (yes — insurance covers AMA discharges), follow-up, and clear return precautions. Do not refuse to provide aftercare as "punishment" — this is itself a liability.
— Identify the legal surrogate per state hierarchy.
— Facilitate family meeting with social work, chaplaincy, palliative care; clarify substituted judgment.
— Time-limited trials of therapy with predefined endpoints can de-escalate impasse.
CCS pearl: When a CCS case involves persistent family-team disagreement about goals of care, the appropriate orders are "palliative care consult" and "ethics consult" alongside continued primary management — not unilateral withdrawal or unilateral continuation. Document the family meeting in the chart.
— Cues: limited education, asks few questions, signs forms without reading, says "yes" to comprehension questions but fails teach-back.
— Intervention: plain language, teach-back, pictographs, written materials at ≤6th-grade reading level.
— Cues: misunderstands "1 in 100" vs "1%," cannot compare risks.
— Intervention: icon arrays, natural frequencies, single denominator.
— Cues: nodding without engagement, family translating.
— Intervention: certified interpreter (in-person/video preferred for complex decisions), translated decision aids.
— Cues: inconsistent choices visit to visit, cannot recount prior discussion.
— Intervention: formal capacity assessment, surrogate involvement, simplified options, repeated visits.
— Cues: catastrophizing, hopelessness, decision paralysis.
— Intervention: acknowledge emotion first (NURSE), defer non-urgent decisions, treat underlying mood.
— Cues: "Just tell me what to do" after a long visit.
— Intervention: split decisions across visits, prioritize most urgent.
— Cues: reluctance to engage, second-guessing recommendations.
— Intervention: acknowledge legitimacy, transparency about uncertainty, continuity of care, cultural humility.
Key distinction: Low health literacy is about reading and processing health information; low numeracy is specifically about numerical reasoning — they overlap but aren't identical. A patient may read well but still misinterpret "1 in 30" risk. Always provide both verbal and visual numerical framing.
— Different clinicians delivering inconsistent messages; the patient is not the problem.
— Solution: shared care plan, structured handoffs (I-PASS), patient-held summary.
— 15-minute visits cannot accommodate complex SDM. The patient who "won't decide" may simply need a return visit.
— Solution: schedule dedicated SDM visit; many CMS-mandated SDM visits are independently billable.
— Clinician focused on screen, not patient; misses nonverbal cues.
— Solution: opening minutes screen-free, summarize while typing, share screen with patient when reviewing data.
— Clinicians offer fewer options or less aggressive workup to certain patients based on race, gender, weight, insurance, perceived "non-compliance."
— Solution: standardized care pathways, bias training, audit/feedback on referral and procedure rates.
— Fee-for-service incentives toward intervention; capitation toward avoidance.
— Disclose to patient when relevant; rely on guidelines, not personal volume.
— Dominant family member overrides patient voice.
— Solution: ask to speak with the patient alone; ensure patient's voice is centered.
— Patient anchored to internet/social media claims.
— Solution: explore the source non-judgmentally, provide vetted alternative, motivational interviewing.
Board pearl: When a stem describes a patient who repeatedly "doesn't follow instructions," the first move is not "discharge from practice" — it is to explore the cause of non-adherence (literacy, cost, side effects, mistrust, depression, side effects, transportation, regimen complexity). The correct exam answer is almost always to investigate, not abandon.
— Options presented (including no treatment).
— Risks/benefits discussed with specific numbers when available.
— Decision aid used and version/date.
— Patient's stated values and how they relate to the choice.
— Questions asked and answered.
— Decision made and rationale.
— Plan for follow-up or reconsideration.
— Medication reconciliation with the patient (not just the chart).
— Teach-back on red-flag symptoms, when to return.
— Confirmed follow-up appointment before discharge (not "call to schedule").
— Written after-visit summary at appropriate reading level.
— Medication affordability addressed (generics, 90-day fills, 340B, patient-assistance programs).
— Hospital → home: 30-day readmission risk reducible by structured handoffs (Project RED, Care Transitions Intervention).
— Hospital → SNF: warm handoff with SBAR; medication list reconciled.
— Specialist → PCP: closed-loop referral with consult note received before next PCP visit.
— Chronic disease care plans revisited at minimum annually and at any clinical inflection.
— Advance directives reviewed when the "5 D's" occur: new Decade of life, Death in family, Diagnosis (serious), Decline in function, Divorce/relationship change.
Step 3 management: Before discharging any patient on a new high-risk medication (anticoagulant, insulin, opioid, immunosuppressant), confirm (1) the patient can state the drug, dose, indication, and key side effect via teach-back; (2) follow-up is scheduled; (3) cost is feasible; (4) monitoring labs are arranged. Missing any of these is a transition-of-care defect.
— Anticoagulation in AF: reassess CHA₂DS₂-VASc and HAS-BLED annually; new falls, new bleeds, new cognitive change, or new comorbidities trigger re-discussion.
— Statins: ASCVD risk recalculated every 4–6 years in eligible adults; lipid panel ~annually once stable.
— Opioids: PDMP every prescription; UDS at least annually; functional assessment each visit; taper discussion ongoing per CDC 2022.
— Screening: age-out timing (e.g., colorectal screening stops at 75–85 per individualized life expectancy and prior screening).
— CollaboRATE (3 items, patient-reported): effort to help understand, listen to what matters most, integrate what matters most.
— SDM-Q-9 and OPTION scales used in research/QI.
— Decisional Conflict Scale pre/post intervention.
— Patient-reported regret at 6–12 months.
— Behavioral change supports (5 A's: Ask, Advise, Assess, Assist, Arrange) for smoking, alcohol, weight, activity.
— Motivational interviewing for ambivalence; transtheoretical model staging.
— Group visits and peer support for diabetes, cardiac rehab, weight management.
— Quality measures (HEDIS, MIPS) increasingly include SDM-sensitive metrics — e.g., LDCT SDM documentation rate, ICD SDM documentation.
— Value-based contracts reward both utilization appropriateness and patient experience (CAHPS), aligning incentives with SDM.
Board pearl: CollaboRATE is the most commonly cited brief patient-reported SDM measure on exam-style stems. If asked how to measure whether SDM occurred from the patient's perspective, the answer is a validated patient-reported scale (CollaboRATE, SDM-Q-9), not chart review or clinician self-report — both of which overestimate SDM quality.
— Emergency exception: consent presumed for life-/limb-saving care when patient cannot consent and no surrogate available; document the emergency.
— Therapeutic privilege: withholding information because disclosure would harm — narrow, disfavored, requires documentation and rare invocation.
— Waiver of consent: patient may decline information ("I don't want to know — do what's best") — honor and document, but still disclose minimum material risks before procedure.
— Minors: assent + parental permission, with exceptions for confidential care (STI, contraception, mental health, substance use treatment) per state.
— Suspected child abuse, elder abuse, dependent-adult abuse.
— Specific infectious diseases (TB, syphilis, HIV in many states, COVID at times).
— Gunshot wounds, stab wounds (state-dependent).
— Imminent threats to identifiable third parties (Tarasoff duty).
— Impaired drivers (varies by state; some require, some permit).
— Medication reconciliation errors are the most common preventable adverse event at hospital discharge.
— Missed test results pending at discharge — explicitly document and arrange follow-up; "no news is good news" is a liability pattern.
— Closed-loop communication on critical results (read-back).
CCS pearl: If a CCS case involves a patient refusing recommended treatment, the correct actions are (1) assess capacity, (2) re-explain risks/benefits/alternatives in plain language, (3) explore reasons for refusal, (4) document the conversation, (5) offer follow-up and clear return precautions, (6) ensure no abandonment. Forcing treatment on a capacitated patient is battery; abandoning them is negligence.
Board pearl: When a question describes a 65-yr-old male asking about PSA screening, the answer is shared decision-making discussion of risks and benefits (USPSTF "C" recommendation, ages 55–69). For age ≥70, recommend against screening. Memorize the age windows for screening SDM thresholds — they appear repeatedly.
Key distinction: When the stem gives you a threshold or preference-sensitive scenario, "shared decision-making" is usually correct; when it gives you a clear-cut indication or contraindication, decisive action is correct. Read the risk numbers carefully to determine which.
— Format risks correctly: absolute risk + natural frequencies + icon arrays beat relative risk and verbal descriptors; NNT translates trial data into patient-relevant numbers; asymmetric framing (RRR for benefit, AR for harm) is a bias trap to avoid.
— Process matters more than outcome: decisional regret tracks process quality; teach-back, decision aids, and structured frameworks (Ask-Tell-Ask, SPIKES, NURSE, BRAN) measurably improve knowledge, reduce decisional conflict, and protect against malpractice claims rooted in communication failure.
— Honor autonomy with structure: capacitated patients may refuse any treatment; surrogates use substituted judgment per state hierarchy; minors get assent + parental permission with confidential-care exceptions; CMS mandates documented SDM visits for LDCT, ICDs, and Watchman; mandatory reporting and Tarasoff override confidentiality only in defined circumstances.
Board pearl: On Step 3, when the stem describes a preference-sensitive decision at a guideline threshold, the answer is almost always "engage in shared decision-making" — not the test, not the drug, not the procedure. Pair this instinct with absolute-risk literacy and teach-back, and you'll handle the entire SDM question bank cleanly.